最新　狭心症診療の実際

出版社： 永井書店
著者：
発行日： 2009-03-20
分野： 臨床医学：内科  >  心臓
ISBN： 9784815918347
電子書籍版： 2009-03-20 （第1版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

8,800 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,400 円(税込)

購入する

商品紹介

本書は，第一線で活躍する循環器専門医が，狭心症の概念，病態，診断，治療など，どの項目をみても世界的レベルのうえで最新の内容を，著者らの実際の臨床でしか培えないエッセンスとともに盛り込んだ狭心症の診療テキストである。

目次

  • 最新　狭心症診療の実際

    ―目次―

    1　狭心症の概念
    2　狭心症の病態生理
    3　狭心症の分類
    4　狭心症の病理像
    5　狭心症をいかに予防するか
    6　メタボリックシンドロームと狭心症
    7　虚血性心疾患と性差
    8　冠動脈硬化症の成因
    9　たこつぼ(型)心筋障害
    10　狭心症の診断における問診のポイント
    11　狭心症の診断における心電図判読のポイント
    12　狭心症の緊急処置と専門医への転送の判断
    13　冠攣縮性狭心症の診断基準
    14　狭心症における心筋シンチグラフィ
    15　狭心症の診断におけるマルチスライスCT(MSCT)
    16　狭心症のカテーテル検査
    17　狭心症における血管内超音波法(IVUS)の意義
    18　狭心症に対するOptical　Coherence　Tomography(OCT)
    19　狭心症の診断における血管内視鏡
    20　狭心症の薬物療法
    21　冠動脈インターベンション(PCI)の適応
    22　Drug-eluting　stentについて
    23　安定狭心症の治療指針
    24　不安定狭心症の治療指針
    25　冠攣縮性狭心症の治療指針
    26　糖尿病を合併する狭心症患者の治療
    27　腎疾患を合併する狭心症患者の治療
    28　脂質異常症を合併する狭心症患者の治療
    29　冠動脈バイパス術(CABG)
    30　重症冠動脈病変に対する冠動脈インターベンション
    31　薬物療法、PCI、CABGの対比
    32　血管新生療法

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

[1] 狭心症の概念

P.5 掲載の参考文献
1) メタボリックシンドローム診断基準検討委員会:メタボリックシンドロームの定義と診断基準. 日本内科学会雑誌94:794-809, 2005.
 
2) 泰江弘文, 小川久雄:狭心症. 内科学書, 改訂第5版, 島田 馨 (編), pp1192-1203, 中山書店, 東京, 1999.
 
3) Yasue H, Nakagawa H, Itoh T, et al:Coronary artery spasm-Clinical features, diagnosisi, pathogenesis, and treatment. Journal of Cardiology 51:2-17, 2008.
 
4) Fuster V, Badimon L, Badimon J, et al:The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engi J Med 326:242-250, 310-318, 1992.
 
5) 小川久雄:Acute Coronary Syndromeの病態. Journal of Cardiology 33 (Supple 1):9-16, 1999.
 
6) Libby P:Molecular Bases ofthe Acute Coronary Syndromes. Circulation 91:2844-2850, 1995.
 

[2] 狭心症の病態生理

P.13 掲載の参考文献
1) Fuster V, Stein B, Ambrose JA, et al:Atherosclerotic plaque rupture and thrombosis; Evolving concept. Circulation 82 (Supp13):1147-1159, 1990.
 
2) Sano K, Kawasaki M, Okubo M, et al:In vivo quantitative tissue characterization of angiographically normal coronary lesions and the relation with risk factors; a study using integrated backscatter intravascular ultrasound. Circ J 69 (5):543-549, 2005.
PubMed
3) Gould KL, Lipscomb K:Effects of coronary stenoses on coronary flow reserve and resistance. Am J Cardiol 34 (1):48-55, 1974.
PubMed
4) Yokoya K, Takatsu H, Suzuki T, et al:Process of progression of coronary arterial lesions from mild or moderate stenosis into severe stenosis; A study based on four serial coronary arteriograms per year. Circulation 100:903-909, 1999.
PubMed
5) Ojio S, Takatsu H, Tanaka T, et al:Considerable Time from the Onset of Plaque Rupture and/ or Thrombi until the Onset of Acute Myocardial Infarction in Human; CAG Findings within One Week before the Onset of Infarction. Circulation 102:2063-2069, 2000.
PubMed
6) Braunwald E, Kloner RA:The stunned myocardium; prolonged, postischemic ventricular dysfunction. Circulation 66 (6):1146-1149, 1982.
PubMed
7) Rahimtoola SH:The hibernating myocardium. Am Heart J 117 (1):211-221, 1989.
PubMed
8) Murry CE, Jennings RB, Reimer KA:Preconditioning with ischemia; a delay of lethal cell injury in ischemic myocardium. Circulation 74 (5):1124-1136, 1986.
PubMed
9) Noda T, Minatoguchi S, Fujii K, et al:Evidence for the delayed effect in human ischemic preconditioning; prospective multicenter study for preconditioning in acute myocardial infarction. J Am Coll Cardiol 34 (7):1966-1974, 1999.
PubMed
10) Prinzmetal M, Kennamer R, Merliss R, et al:Angina pectoris 1. Avariant form of angina pectoris; preliminary report. Am J Med 27:375-388, 1959.
 
11) Furchgott RF, Zawadzki JV:The obligatory role of endothelial cells inthe relaxation of arterial smooth muscle by acetylcholine. Nature 288 (5789):373-376, 1980.
 
12) Yasue H, Matsuyama K, Matsuyama K, et al:Responses of angiographically normal human coronary arteries to intracoronary injection of acetylcholine by age and segment; Possible role of early coronary atherosclerosis. Circulation 81 (2):482-490, 1990.
PubMed
13) Katsumata N, Shimokawa H, Seto M, et al:Enhanced myosin light chain phosphorylations as acentral mechanism for coronary artery spasm in a swine model with interleukin-1beta. Circulation 96 (12):4357-4363, 1997.
 
14) Stern S, Tzivoni D:Early detection of silent ischaemic heart disease by 24-hour electrocardiographic monitoring of active subjects. Br Heart J 36 (5):481-486, 1974.
PubMed

[3] 狭心症の分類

P.18 掲載の参考文献
1) World Health Organization:International Statistical Classification of Disease and Relate Health Organization. pp477-482, WHO, Geneva, 1992.
 
2) Worid Health Organization:Tech. Report Series, p231, WHO, Geneva, 1962.
 
3) Fuster V, Badimon L, Chesebro JH:The pathogenesis of coronary artery disease and the acute coronary syndromes. N Eng J Med 326:242-250, 1992.
 
4) Braunwald E, et al:Diagnosing and managing unstable angina; Agency for Health Care Policy and Research. Circulation 90:613, 1994.
PubMed
5) Campeau L:Grading of angina pectoris (letter). Circulation 54:522-523, 1976.
PubMed
6) Austin WG, et al:A reporting system on patients evaluated for coronary artery disease. Report of the adhoc committee for grading of coronary artery disease; Council on Cardiovascular Surgery, American Heart Association. Circulation 51:5-40, 1975.
 
7) Braunwald E:Unstable angina; a classification. Circulation 80:410-414, 1989.
PubMed
8) Cohn PF:Silent myocardial ischemia; classification, prevalence and prognosis. Ann Intern Med 109:312-317, 1988.
PubMed

[4] 狭心症の病理像

P.23 掲載の参考文献
1) Kumar V, Abbas AK, Fausto N:Robbins and Cotran Pathologic basis of disease. 7th ed, pp571-575, Elsevier Saunders, Philadelphia, 2005.
 
2) Williams KJ, Tabas I:The response to retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 15:551-561, 1995.
PubMed
3) Ross R:Atherosclerosis-an inflammatory disease. N Engl J Med 340:115-126, 1999.
PubMed
4) Hangartner JR, Charleston AJ, Davies MJ, et al:Morphological characteristics of clinically significant coronary artery stenosis in stable angina. Br Heart J 56:501-508, 1986.
PubMed
5) Flugelman MY, Virmani R, Correa R, et al:Smooth muscle cell abundance and fibroblast growth factors in coronary lesions of patients with nonfatal unstable angina; Aclue to the mechanism of transformation from the stable to the unstable clinical state. Circulation 88:2493-2500, 1993.
 
6) Arbustini E, De Servi S, Bramucci E, et al:Comparison of coronary lesions obtained by directional coronary atherectomy in unstable angina, stable angina, and restenosis after either atherectomy or angioplasty. Am J Cardiol 75:675-682, 1995.
PubMed
7) Depre C, Wijns W, Robert AM, et al:Pathology of unstable plaque; correlation with clinical severity of acute coronary syndromes. J Am Coll Cardiol 30:694-702, 1997.
PubMed
8) Terazawa M, Morimoto S, Hirayama H, et al:Histopathologic evaluation of coronary artery thrombi obtained by directional coronary atherectomy in patients with restenosis-induced unstable angina pectoris. Jpn Circ J 65:505-508, 2001.
PubMed
9) Hatakeyama K, Hao H, Imamura T, et al:Relation of CD39 to plaque instability and thrombus formation in directional atherectomy specimens from patients with stable and unstable angina pectoris. Am J Cardiol 95:632-635, 2005.
PubMed
10) Ishikawa T, Hatakeyama K, lmamura T, et al:Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris. Am J Cardiol 91:287-292, 2003.
PubMed
11) Nishihira K, Imamura T, Yamashita A, et al:Increased expression of interleukin-18 in unstable plaque obtained by directional coronary atherectomy. Eur Heart J 27:1685-1689, 2006.
 
12) Nishihira K, Imamura T, Hatakeyama K, et al:Expression of interleukin-18 in coronary plaque obtained by atherectomy from patients with stable and unstable angina. Thromb Res 121:275-279, 2007.
PubMed
13) Fuster V:Mechanisms leading to myocardial infarction; insights of vascular biology. Circulation 90:2126-2146, 1994.
PubMed
14) Roberts WC, Virmani R:Quantification of coronary arterial narrowing in clinically-isolated unstable angina pectoris; An analysis of 22 necropsy patients. Am J Med 67:792-799, 1979.
PubMed
15) Nishihira K, Yamashita A, lmamura T, et al:Thioredoxin incoronary culprit lesions; Possible relationship to oxidative stress and intraplaque hemorrhage. Atherosclerosis 201:360-367, 2008
 

[5] 狭心症をいかに予防するか

P.31 掲載の参考文献
1) Libby P:What Have We Learned About the Biology of Atherosclerosis? The Role of Inflammation. Am J Cardiol 88 (suppl):3J-6 J, 2001,
 
2) 日本循環器学会学術委員会:虚血性心疾患の一次予防ガイドライン. 2006年度改訂版, 日本循環器学会, 東京, 2006.
 
3) Kannel WB, et al:Cholesterol in the prediction of atherosclerotic disease; New perspectives based on the Framingham study. Ann Intern Med 90:85-91, 1979.
PubMed
4) Forstermann U, Munzel T:Endothelial nitric oxide synthase in vascular disease; from marvel to menace. Circulation 113 (13):1708-1714 (Review), 2006.
PubMed
5) 日本高血圧学会 (編):高血圧治療ガイドライン2009. ライフサイエンス出版, 東京, 2009.
 
6) 日本動脈硬化学会 (編):動脈硬化性疾患予防ガイドライン2007年版. 協和企画, 東京, 2008.
 
7) The medical research council's general practice research framework; Thrombosis prevention trial:randomised triai of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 351:233-241, 1998.
 
8) Hansson L, et al:Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension; principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755-1762, 1998.
PubMed

[6] メタボリックシンドロームと狭心症

P.41 掲載の参考文献
1)中尾一和, 松澤佑次, 島本和明, ほか:メタボリックシンドローム; 病院解明と予防・治療の 最新戦略.日本臨牀64 (増刊号9):1-764, 2006.
 
2) 前田和久, 梁 美和, 前田法一, ほか:内臓脂肪症候群; メタボリックシンドロームとして. 改訂版, 船橋 徹, 中村 正 (編), 松澤佑次 (監), pp10-186, 医薬ジャーナル社, 東京, 2006.
 
3) Kannel WB, Castelli WP, Gordon T:Cholesterol in the prediction of atherosclerotic disease; New perspectives based on the Framingham study. Ann Intern Med 90 (1):85-91, 1979.
PubMed
4) メタボリックシンドローム診断基準検討委員会:メタボリックシンドロームの定義と診断基準. 日本内科学会雑誌94:188-203, 2005.
 
5) Funahashi T, Nakamura T, Shimomura I, et al:Role of adlpocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 38:202, 1999.
PubMed
6) 岸田 堅, 船橋 徹:心臓病と肥満; メタボリックシンドロームを中心に. 循環器疾患; 最新の治療; 2008-2009, pp479-483, 南江堂, 東京, 2008.
 
7) 岸田 堅, 船橋徹:メタボリックシンドロームの概念と診断.治療89:2314-2319, 2007.
 
8) World Health Organization:Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Part I:Diagnosis and Classification of Diabetes Mellitus. World Health Organization, Geneva, 1999.
PubMed
9) Balkau B, et al:Comment on the provisional report from the WHO consultation; European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16:442-443, 1999.
 
10) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults:Executive Summary of The Third Report of The National Cholesterol Education Program Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults. JAMA 285:2486-2497, 2001.
 
11) Einhorn D, et al:American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9:237-252, 2003.
 
12) Ford ES:Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U. S. Diabetes Care 28:2745-2749, 2005.
 
13) American Heart Association; National Heart, Lung, and Blood Institue; Grundy SM, et al:Diagnosis and management of the metabolic syndrome; An American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev 13:322-327, 2005.
PubMed
14) 肥満症治療ガイドライン作成委員会:肥満症治療ガイドライン2006. 日本肥満学会雑誌12 (臨時増刊号):1-91, 2006.
 
15)Ryo M, et ai. Adiponectin as a biomarker of the metabolic syndrome. Circ J 68. 975, 2004.
 
16)Ouchi N, et al:Novel modulator for endothelial adhesion molecules; adipocyte-derived plasma protein adiponectin. Circulation 100:2473, 1999.
PubMed
17)Kumada M, et al:Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85, 2003.
PubMed
18)Pischon T, Girman CJ, Hotamisligil GS, et al:Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (14):1730-1737, 2004.
PubMed
19)Otsuka F, Sugiyama S, Kojima S, et al:Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease. J Am Coll Cardiol 48 (6):1155-1162, 2006.
PubMed
20)Nakamura Y, Shimada K, Fukuda D, et al:lmplications of plasma concentrations of a diponectin in patients with coronary artery disease. Heart 90 (5):528-533, 2004.
 
21)Maruyoshi H, Kojima S, Otsuka F, et al:Hypoadiponectinemia is associated with coronary artery spasm in men. Circ J 69 (9):1154-1156, 2005.
PubMed

[7] 虚血性心疾患と性差

P.52 掲載の参考文献
1) Yasue H, Matsuyama K, Matsuyama K, et al:Responses of angiographically normal human coronary arteries to intracoronary injection of acetylcholine by age and segment possible role of early coronary atherosclerosis. Circulation 81:482-493, 1990.
PubMed
2) Celermajer DS, Sorensen KE, Spiegelhalter DJ, et al:Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 24:471-476, 1994.
PubMed
3) Kosuge M, Kimura K, Kojima S, et al:Sex differences in early mortality of patients undergoing primary stenting for acute myocardial infarction. Circ J 70:217-221, 2006.
PubMed
4) Koek HL, de Bruin A, Gast F, et al:Short-and long-term prognosis after acute myocardial infarction in men versus women. Am J Cardiol 98:993-999, 2006.
 
5) 豊福 守, 後藤葉一, 松本高宏, ほか:日本人若年女性における急性心筋梗塞の臨床的特徴. J Cardiol 28:313-319, 1996.
 
6) Kawano H, Ogawa H:Endothelial function and coronary spastic angina. Intern Med 44:91-99, 2005.
PubMed
7) Kawano H, Motoyama T, Ohgushi M, et al:Menstrual cyclic variation of myocardial ischemia in premenopausal women with variant angina. Ann Intern Med 135:977-981, 2001.
PubMed
8) Lloyd GW, Patel NR, McGing E, et al:Does angina vary with the menstrual cycle in women with premenopausal coronary artery disease? Heart 84:189-192, 2000.
PubMed
9) Kawano H, Motoyama T, Kugiyama K, et al:Gender difference in improvement of endothelium-dependent vasodilation after estrogen supplementation. J Am Coll Cardiol 30:914-919, 1997.
PubMed
10) Kawano H, Motoyama T, Hirai N, et al:Estradiol supplementation suppresses hyperventila tion-induced attacks in postmenopausal women with variant angina. J Am Coll Cardiol 37:735-740, 2001.
 
11) Rosano GMC, Sarrel PM, Poole-Wilson PA, et al:Beneficial effect of oestrogen on exercise induced myocardial ischaemia in women with coronary artery disease. Lancet 342:133-136, 1993.
 
12) Sullivan AK, Holdright DR, Wright CA, et al:Chest pain in women; Clinical, investigative, and prognostic features. BMJ 308:883-886, 1994.
PubMed
13) Kaski JC:Cardiac syndrome X and microvascuiar angina. Chest pain with normal coronary angiograms; pathogenesis, diagnosis, and management, Kaski JC (ed), pp1-12, Kluwer Academic Publishers, Boston, 1999.
 
14) Inobe Y, Kugiyama K, Morita E, et al:Role of adenosine in pathogenesis of syndrome X, J Am Coll Cardiol 28:890-896, 1996.
 
15) Maseri A, Crea F, Kaski JC, et al:Mechanism of angina pectoris in syndrome X. J Am Coll Cardioi 17:499-506, 1991.
 
16) Moriyama Y, Yasue H, Yoshimura M, et al:The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure. J Clin Endocrinol Metab85:1834-1840, 2000.
 
17) Lamberts SW, van den Beid AW, van der Lely AJ:The endocrinology of aging. Science 278:419-424, 1997.
 
18) Liu D, Dillon JS:Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by aspecific plasma membrane receptor coupled to Galpha (i2, 3). J Biol Chem 277:21379-21388, 2002.
 
19) Hayashi T, Esaki T, Muto E, et al:Dehydroepiandrosterone retards atherosclerosis formation through its conversion to estrogen. Arterioscier Thromb Vasc Biol 20:782-792, 2000.
PubMed
20) Kawano H, Yasue H, Kitagawa A, et al:Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocri & Metab 88:3190-3195, 2003.
 
21) Writing group for the Women:s Health Initiative Investigators:Risks and benefits of estrogen and progestin in healthy postmenopausal women. JAMA 288:321-333, 2002.
 
22) Hulley S, Grdy D, Bush T, et al:Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post menopausal women. JAMA 280:605-613, 1998.
 
23) Kawano H, Soejima H, Kitagawa A, et al:Sex differences of risk factors for acute myocardial infarction in Japanese patients. Circ J 70:513-517, 2006.
PubMed

[8] 冠動脈硬化症の成因

P.60 掲載の参考文献
1) Ross R:Atherosclerosis; an inflammatory disease. N Engl J Med 340 (2):115-126, 1999.
PubMed
2) Libby P:Inflammation In atherosclerosis. Nature 420 (6917):868-874, 2002.
PubMed
3) Libby P:Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104 (3):365-372, 2001.
PubMed
4) Dawber TR, Kannel WB, Revotskie N, et al:Some factors associated with the development of coronary heart disease; six years:follow-up experience In the Framlingham study. Am J Public Health 49:1349-1356, 1959.
 
5) Ridker PM, et al:Development and validation of improved algorithms for the assessment of global cardiovascular risk in women; the Reynolds Risk Score. JAMA 297 (6):611-619, 2007.
PubMed
6) 日本動脈硬化学会 (編):動脈硬化性疾患予防ガイドライン. 2007年版, 協和企画, 東京, 2007.
 
7) Nordestgaard BG, Benn M, Schnohr P, et al:Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298 (3):299-308, 2007.
PubMed
8) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2009, 日本高血圧学会, 東京, 2009.
 
9) Dzau V:The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Supρ123 (1):S9-S17, 2005.
 
10) Yasue H, Hirai N, Mizuno Y, et al:Low-Grade Inflammation, Thrombogenicity, and Atherogenic Lipid Profile in Cigarette Smokers. Circ J 70 (1):8-13, 2006.
PubMed
11) 日本循環器学会, ほか:循環器病の診断と治療に関するガイドライン (2006-2007年度合同研 究班報告). 冠攣縮性狭心症の診断と治療に関するガイドライン. Circ・J 72 (Suppl IV):1195-1238, 2008.
 
12) Haffner SM, Lehto S, ROnnemaa T, et al:Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. NEngl J Med339 (4):229-234, 1998.
PubMed
13) Yamagishi S, Nakamura K, lmaizumi:Advanced glycation end products (AGEs) and diabetic vascular complications. Curr Diabetes Rev 1 (1):93-106, 2005.
PubMed
14) Nissen SE, Nicholls SJ, Wolski K, et al:Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease; the STRADIVARIUS randomized controlled trial. JAMA 299 (13):1547-1560, 2008.
PubMed
15) Koenig W, et al:Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thrombo Vasc Biol 27:15-26, 2006.
 

[9] たこつぼ(型)心筋障害

P.71 掲載の参考文献
1) 佐藤 光, 立石博信, 内田俊明, ほか:多枝spasmにより特異な左室造影像「ツボ型」を示したstunned myocardium. 臨床からみた心筋細胞傷害; 虚血から心不全まで, 児玉和久, 土師 一夫, 堀 正二 (編), pp56-64, 科学評論社, 東京, 1990.
 
2) Dote K, Sato H, Tateishi H, et al:Myocardial stunning due to simultaneous multivessel spasms; areview of 5 cases[in Japanese with English abstract]. J Cardiol 21:203-214, 1991.
 
3) Kawai S, Suzuki H, Yamaguchi H, et al:Ampulla Cardiomyopathy ("Takotsubo"cardiomyopathy) ; reversible left ventricular dysfunction with ST segment elevation. Jpn Circ J 64:156-159, 2000.
 
4) Owa M, Aizawa K, Urasawa N, et al:Emotional stress-induced"ampulla cardiomyopath"; A dicrepancy exists between metabolic and sypathetic innervation imaging in the recovery. Jpn Circ J 65:349-352, 2001.
 
5) Tsuchihashi K, Ueshima K, Uchida T, et al:Transient Left Ventricular Apical Ballooning Wthout Coronary Artery Stenosis; A Novel Heart Syndrome Mimicking Acute Myocardial Infarction. J Am Coll Cardiol 38:11-18, 2001.
 
6) Kurisu S:Tako-tsubo like left ventricular dysfunction with ST segment elevation; a novel cardiac syndrome mimicking acute myocardial infarction. Am Heart J 143:448-455, 2002.
PubMed
7) Matsuoka K, Okubo S, Fujii E, et al:Evaluation of the arrhythmogenecity of stress-induced "Takotsubo cardiomyopathy"from the time course of the 12-lead surface electrocardiogram. Am J Cardiol 92:239-233, 2003.
 
8) Pavin D, Le Breton H, Daubert C:Human stress cardimyopathy mimicking acute myocardial syndrome. Heart 78:509-511, 1997.
 
9) Sharkey SW, Shear W, Hodges M, et al:Reversible myocardial contraction abnormalities in patients with an acute noncardiac illness. Chest 114:98-105, 1998.
PubMed
10) Desnet WJ, Adriaenssens BF, Dens JA:Apical ballooning of the left ventricle; first series in white patients. Heart 89:1027-1031, 2003.
 
11) Wittstein HS, Thieman DR, Lima JA, et al:Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engi J Med 352:539-548, 2005.
 
12) 河合祥雄:たこつぼ心筋障害 (たこつぼ心筋症) 診断の手引き (第2案) 作成過程. 心臓36:466-468, 2004.
 
13) Bybee KA, Kara T, Prasad A, et al:Systemic review; transient left ventricular apical ballooning; asyndrome that mimic ST-elevation myocardial infarction. Ann Int Med 141:858-865, 2004.
 
14) Prasad A, et al:Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy) ; A mimic of acute myocardial infarction. Am Heart J 155:408-417, 2008.
 
15) Yoshioka T, Hashimoto A, Tsuchihashi K, et al:Clinical implications of midventricular obstruction and intravenous propranolol use in transient left ventricular apical ballooning (Tako-tsubo cardiomyopathy). Am Heart J 155:526. e1. e7, 2008.
 

[10] 狭心症の診断における問診のポイント

P.82 掲載の参考文献
1) 日本循環器学会, ほか:急性冠症候群の診療に関するガイドライン (2007年改訂版). Circ J 71:Suppl IV, 2007.
 
2) 日本循環器学会, ほか:大動脈瘤・大動脈解離診療ガイドライン (2006年改訂版) ; 循環器病の診断と治療に関するガイドライン (2004～2005年度合同研究班報告). Circ J 70 (Suppl IV):1569-1646, 2006.
 
3) 日本循環器学会, ほか:肺血栓塞栓症および深部静脈血栓症の診断・治療・予防に関するガイドライン; 循環器病の診断と治療に関するガイドライン (2002～2003年度合同研究班報告). Circ J 68 (Suppl IV):1079-1152, 2004.
 
4) Braunwald E, Mark DB, Jones RH, et al:Unstabie angina; diagnosis and management. Clinical Practice Guideline No. 10, pp94-602, AHCPR Pub, Rockville, Md, 1994.
 
5) Campeau L:Grading of angina pectoris. Circulation 54:522-523, 1976.
PubMed
6) Report of the Ad Hoc Committee for Grading of Coronary Aretry Disease, Council on Cardiovascular Surgery, American Heart Association:A reporting system on patients evaluated for coronary artery disease. Circulation 51:5-40, 1975.
 
7) Braunwald E:Unstable angina; Aclassification. Circulation 80:410-414, 1989.
 
8) Antman EM, Cohen M, Bernink PJLM, et al:The TIMI risk score for unstable angina/non-ST elevation M; A method for prognostication and therapeutic decision making. JAMA 284:835-842, 2000.
 
9) Braunwald E, Antman EM, Beasley JW, et al:ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction-2002; Summary article. Circulation 106:1893-1900, 2002.
PubMed

[11] 狭心症の診断における心電図判読のポイント

P.96 掲載の参考文献
1) Engelen DJ, Gorgels AP, Cheriex EC, et ai:Value Of the electrocardiogram in localizing the occlusion site in the left anterior descending coronary artery in acute anterior myocardial infarction. J Am Coll Cardiol 342:389-395, 1999.
 
2) Gorgels AP, VOs MA, Mulleneers R, et al:Value of the electrocardiogram in diagnosing the number of severely narrowed coronary arteries in rest angina pectoris. Am J Cardiol 72:999-1003, 1993.
PubMed
3) Kosuge M, Kimura K, lshikawa T, et al:Combined prognostic utility of ST segment in lead aVR and troponin T On admission in non-ST-segment elevation acute coronary syndromes. Am J Cardiol 97:334-339, 2006.
 
4) Kaul P, Newby LK, Fu Y, et al:Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. J Am Coll Cardiol 41:371-380, 2003.
PubMed
5) Surawicz B:Uwave; facts, hypothesis, misconceptions, and misnomers. J Cardiovasc Electrophysio 19:1117-1128, 1998.
 
6) Sicouri S, Antzelevitch C:A subpopulation of cells with unique electrophysiological properties in the deep subepicardium of the canine ventricle; The M cell. Cir Res 68:1729-1741, 1991.
 
7) Miwa K, Miyagi Y, Fujita M, et al:Transient terminal U wave inversion as a more specific marker for myocardial ischemia. Am Heart J 125:981-986, 1993.
PubMed
8) Miwa K, Nakagawa K, Hirai T, et al:Exercise-induced U-wave alterations as a marker of well developed and well-functioning collateral vessels in patients with effort angina. J Am Coll Cardiol 35:757-763, 2000.
 
9) Miranda CP, Liu J, Kadar A, et al:Usefulness of exercise-induced ST-segment depression in the inferior leads during exercise testing as a markerforcoronary artery disease. Am J Cardiol 69:303-307, 1992.
PubMed
10) Ogawa H, Yasue H, Oshima S, et al:Circadian variation of plasma fibrinopeptide A level in patients with variant angina. Circulation 80:1617-1626, 1989.
PubMed

[12] 狭心症の緊急処置と専門医への転送の判断

P.106 掲載の参考文献
1) 山口 徹, ほか:循環器病の診断と治療に関するガイドライン; 急性冠症候群の診療に関するガイドライン (2007年改訂版) (Guidefiines for management of acute coronary syndrome without persistent ST segment elevation http://www.j-circ.or.jp/guideline/pdf/JCS2007_yamaguchi.pdf)
 
2) The TIMI III B investigators:Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction; results of the TIMI IIIB trial. Circulation 89:1545-1556, 1994.
 
3) ISIS-2 (second international study of infarct survival) collaborative group:Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction; ISIS-2. Lancet 13:349-360, 1988.
 
4) Gruppo ltaliano per lo studio della streptochinasi nell'infarto miocardico (GISSI:Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 22:397-402, 1986.
 
5) Austen WG, Edwards JE, et al:A reporting system on patients evaluated for coronary artery disease; Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 51 (Suppl):5-40, 1975.
 
6) Braunwald E:Unstable angina; A classification. Circulation 80:410-414, 1989.
PubMed
7) Antman EM, Cohen M, et al:The TIMI risk score for unstable angina/non-ST elevation Ml; A method for prognostication and therapeutic decision making. JAMA 284:835-842, 2000.
 
8) Lee CH, Tan M, Yan AT, et al:Use of cardiac catheterization for non-ST-segment elevation acute coronary syndromes according to initial risk; Reasons why physicians choose not to refer their patients. Arch Intern Med 168:291-296, 2008.
 

[13] 冠攣縮性狭心症の診断基準

P.114 掲載の参考文献
1) Pristipino C, Beltrame JF, Finocchiaro ML, et al:Major racial differences in coronary constrictor response between Japanese and Caucasians with recent myocardial infarction. Circulation 101:1102-1108, 2000.
PubMed
2) 冠攣縮性狭心症の診断と治療に関するガイドライン. Circ J 72 (suppl IV):1195-1238, 2008.
 
3) Yasue H, Kugiyama K:Coronary spasm; clinical features and pathogenesis. Intern Med 36:760-765, 1997.
PubMed
4) Yasue H, Omote S, Takizawa A, et al:Circadian variation of exercise capacity in patients with Prinzmetal's variant angina; role of exercise-induced coronary arterial spasm. Circulation 59:938-948, 1979.
PubMed
5) Nakao K, Ohgushi M, Yoshimura M, et al:Hyperventilation as a specific test for diagnosis of coronary artery spasm. Am J Cardiol 80:545-549, 1997.
PubMed
6) Schachinger V, Britten MB, Zeiher AM:Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary hea rt disease. Circulation 101:1899-1906, 2000.
 
7) Yoshida T, Kawano H, Miyamoto S, et al:Prognostic value of flow-mediated dilation of the brachial artery in patients with cardiovascular disease. Intern Med 45:575-589, 2006.
PubMed
8) Kaski JC, Crea F, Meran D, et al:Local coronary supersensitivity to diverse vasoconstrictive stimuli in patients with variant angina. Circulation 74:1255-1265, 1986.
PubMed
9) Raizner AE, Chahine RA, Ishimori T, et al:Provocation of coronary artery spasm by the cold pressor test; Hemodynamic, arteriographic and quantitative angiographic observations. Circulation 62:925-932, 1980.
PubMed
10) Yoshida K, Utsunomiya T, Morooka T, et al:Mental stress test is an effective inducer of vasospastic angina pectoris; comparison with cold pressor, hyperventilation and master two step exercise test. Int J Cardiol 70:155-163, 1999.
PubMed
11) Yasue H, Horio Y, Nakamura N, et al:Induction of coronary artery spasm by acetylcholine in patients with variant angina; possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. Circulation 74:955-963, 1986.
PubMed
12) Okumura K, Yasue H, Matsuyama K, et al:Sensitivity and specificity of intracoronary injection of acetylcholine forthe induction of coronary artery spasm. J Am Coll Cardiol 12:883-888, 1988.
 
13) Okumura K, Yasue H, Horio Y, et al:Multivessel coronary spasm in patients with variant angina; astudy with intracoronary injection of acetylcholine. Circulation 77:535-542, 1988.
 
14) Sueda S, lzoe Y, Kohno H, et al:Need for documentation of guidelines for coronary artery spasm:an investigation by questionnaire in Japan. Circ J 69:1333-1337, 2005.
 
15) Curry RC Jr, Pepine CJ, Sabom MB, et al:Similarities of ergonovine-induced and spontaneous attacks of variant angina. Circuiation 59:307-312, 1979.
PubMed
16) Hackett D, Larkin S, Chierchia S, et al:Induction of coronary artery spasm by a direct local action of ergonovine. Circulation 75:577-582, 1987.
PubMed
17) 石瀬昌三, 文字 直, 高桑 健, ほか:選択的冠動脈内エルゴノビン投与による冠スパスムの検討. 呼吸と循環35:191-195, 1987.
 
18) Goldberg S, Lam W, Mudge G, et ai:Coronary hemodynamic and myocardial metabolic alterations accompanying coronary spasm. Am J Cardiol 43:481-487, 1979.
 
19) Mohri M, Koyanagi M, Egashira K, et al:Angina pectoris caused by coronary microvascular spasm. Lancet 351:1165-1169, 1998.:
PubMed
20) 泰江弘文, 水野雄二, 原田栄作, ほか:冠痙攣縮性狭心症の臨床, 発生機序ならびに治療; 最新の知見を踏まえて. 日本医事新報4258:12-17, 2005.
 
21) Sueda S, Ochi N, Kawada H, et al:Frequency of provoked coronary vasospasm in patients undergoing coronary arteriography with spasm provocation test of acetylcholine. Am J Cardiol 83:1186-1190, 1999.
PubMed

[14] 狭心症における心筋シンチグラフィ

P.127 掲載の参考文献
1) 20e03-2004年度合同研究班報告:心臓核医学検査ガイドライン (JCS2005). Circ.J 69 (suppl IV):1125-1207, 2005.
 
2) Klocke FJ, Baird MG, Lorell BH, et al:ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging-executive summary; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide lmaging). Circulation 108:1404, 2003.
 
3) Fukuyama T, Nakamura M, Nakagaki O, et al:Reduced reflow and diminished uptake of 86Rb after temporary coronary occlusion. Am J Physiol 234:H724-H729, 1978.
PubMed
4) Garber AM, Hlatky MA:Stress testing for the diagnosis of coronary heart disease. Up To Date Web site[Available at:http://www.uptodate.com (accessed April 24, 2008) ].
 
5) Nishimura T, Nakajima K, Kusuoka H, et al:Prognostic study of risk stratification among Japanese patients with ischemic heart disease using gated myocardial perfusion SPECT; J ACCESS study. Eur J Nucl Med Mol Imaging 35:319-328, 2008.
PubMed
6) Shaw LJ, et al:The economic consequences of available diagnostic and prognostic strategies for the evaluation of stable angina patients; an observational assessment of the value of precatheterization ischemia:Economics Of Noninvasive Diagnosis (END) Multicenter Study Group. J Am Coll Cardiol 33 (3):661-669, 1999.
 
7) Gibbons RJ, Abrams J, Chatterjee K, et al:ACC/AHA 2002 guideline update for the management of patients with chronic stable angina[Available at:www.acc.org/qualityandscience/clinical/statements.htm (accessed September 24, 2007).
 
8) Imamura Y, Fukuyama T, Nishimura S, et al:Normal myocardial perfusion scan potends a benign prognosis independent from the pretest probability of coronary artery disease; Subanalysis of the J-ACCESS study (投稿中).
 
9) BOden WE, O'Rourke RA, Teo KK, et al:Optimal medical therapy with or without PCI for stable coronary disease. N Engi J Med 356 (15):1503-1516, 2007.
 
10) Hachamovitch R, Hayes SW, Friedman JD, et al:Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 107:2900-2907, 2003.
PubMed
11) Smith SC, Feldman TE, Hirshfeld JW, et al:ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention; Summary Article. Circulation 113:156-175, 2005.
PubMed
12) Schuijf JD, Wijins W, Jukema JW, et al:Relationship between noninvasive coronary angiography with multi-slice computed tomography and myocardial perfusion imaging. J Am Coll Cardiol 48:2508-2514, 2006.
 
13) Gaemperli O, et al:Cardiac image fusion from stand-alone SPECT and CT:clinical experience. J Nucl Med 48:696-703, 2007.
PubMed
14) Rispler S, et al:Integrated single-photon emission computed tomography and computed tomography coronary angiography for the assessment of hemodynamically significant coronary artery lesions. J Am Coll Cardiol 49:1059-1067, 2007.
PubMed

[15] 狭心症の診断におけるマルチスライスCT(MSCT)

P.139 掲載の参考文献
1) Schroeder S, Kopp AF, Baumbach A, et al:Noninvasive detection and evaluation of atherosclerotic coronary plaques with multislice computed tomography. J Am Coll Cardiol 37:1430-1435, 2001.
PubMed
2) Ehara M, Kawai M, Surmely JF, et al:Diagnostic accuracy of coronary in-stent restenosis using 64-slice computed tomography; comparison with invasive coronary angiography. J Am Coll Cardiol 49:951-959, 2007.
PubMed
3) Meyer TS, Martinoff S, Hadamitzky M, et al:lmproved noninvasive assessment of coronary artery bypass grafts with 64-slice computed tomographic angiography in an unselected patient population. J Am Coll Cardiol 49:946-950, 2007.
 
4) Jinzaki M, Sato K, Tanami Y, et al:Novel method of displaying coronary CT angiography; Angiographic view. Circ J 70:1661-1662, 2006.
PubMed
5) Kitagawa T, Yamamoto H, Ohhashi N, et al:Comprehensive evaluation of noncalcified coronary plaque characteristics detected using 64-slice computed tomography in patients with proven or suspected coronary artery disease. Am Heart J 154:1191-1198, 2007.
PubMed
6) Vanhoenacker PK, Heijenbrok-Kal MH, Van Heste R, et al:Diagnostic performance of multidetector CT angiography for assessment of coronary artery disease; meta-analysis. Radiology 244:419-428, 2007.
PubMed
7) Kitagawa T, Yamamoto H, Horiguchi J, et al:Characterization of noncalcified coronary plaques and identification of culprit Iesions in patients with acute coronary syndrome by 64 slice computed tomography. J Am Coll Cardiol lmg 2:153-160, 2009.
 
8) Hirai N, Horiguchi J, Fujioka C, et al:Prospective versus retrospective ECG-gated 64 detector coronary CT angiography; assessment of image quality, stenosis, and radiation dose. Radiology 248:424-430, 2008.
PubMed

[16] 狭心症のカテーテル検査

P.151 掲載の参考文献
1) Klocke FL:Measurement of coronary blood flow and degree of stenosis. J Am Coll Cardiolo 1:31-41, 1983.
 
2) Austen GA, et al:A reporting system on patients evaluated for coronary artery disease; Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association, Circulation 51 (Suppl 4):5-40, 1975.
 
3) Yasue H, et al:Induction of coronary artery spasm by acetylcholine in patients with variant angina; possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. Circulation 74:955-963, 1986.
PubMed
4) Sakamoto T, et al:Association of patency Of the infarct-related coronary artery with plasma leveis of plasminogen activator inhibitor activity in acute myocardial infarction. Am J Cardiol 70:271-276, 1992.
 

[17] 狭心症における血管内超音波法(IVUS)の意義

P.156 掲載の参考文献
1) Mintz GS, Painter JA, Plchard AD, et al:Atheroscleosis In angiographically"normal" coronary artery reference segments; an intravascular ultrasound study with clinical correlations. J Am Coll Cardiol 25:1479-1489, 1995.
 
2) Okura H, Morino Y, Oshima A, et al:Preintervention arterial remodeling affects clinical outcome following stenting; an Intravascular ultrasound study. J Am Coll Cardiol 37:1031-1035, 2001.
PubMed
3) Prati F, Di Mario C, Moussa l, et al:Instent nointimal poliferation correlates with the amount of residual plaque burden outside the stent; an intravascular ultrasound study. Circulation 99:1011-1014, 1999.
 
4) Dangas G, Mintz GS, Mehran R, et al:Preintervention arterial remodeling as an independent predictor of target-lesion revascularization after nonstent coronary intervention ; an analysis of 777 lesions with intravascular ultrasound imaging. Circulation 99:3149-3154, 1999.
PubMed
5) Pijls NHJ, de Bruyne B, Peels K, et al:Measurement of fractional flow reserve to reserve to assess thethe functional severity of coronary-artery stenoses. N Engl J Med 334:1703-1708, 1996.
 
6) Nishioka T, Amanullah AM, Luo AM, et al:Clinical validation of intravascular imaging for assessment of coronary stenosis severity; comparison with stress myocardial perfusion imaging. J Am Coll Cardiol 33:1870-1878, 1999.
 
7) Takagi A, Tsurumi Y, lshii Y, et al:Clinical potential of intravascular ultrasound for physiological assessment of coronary stenosis; relationship between quantitative ultrasound tomography and pressure-derived fractional flow reserve. Circulation 100:250-255, 1999.
 
8) Abizaid AS, Mintz GS, Mehran R, et al:Long-term follow-up after transluminal coronary angioplasty was not performed based on intravascular uitrasound findings; importance of lumen dimension. Circulation 100:256-261, 1999.
PubMed
9) Kotani J, Mintz GS, Rai PB, et al:Pattern of lesion calcification in infarct-related arteries; an intravascular ultrasound analysis of 250 patients with acute myocardial infarction. J Am Coll Cardiol 43:supplement 40 A, 2004.
 
10) Mintz GS, Nissen SE, Anderson WD, et al:Standards for the acquisition, measurement, and reporting of intravascular ultrasound studies; a report of the American College of Cardiology Task Force on Clinical Expert Cosensus Documents. J Am Coll Cardiol 37:1478-1492, 2001.
 
11) Elezi S, Kastrati A, Neumann F-J, et al:Vessei size and long-term Outcome after coronary stent placement. Circulation 98:1875-1880, 1998.
 
12) Abizaid AS, Mintz GS, Abizaid A, et al:One-year follow-up after intravascular ultrasound assessment of moderate left main coronary artery disease in patients with ambiguous angiograms. J Am Coll Cardiol 34:707-715, 1999.
PubMed
13) Jasti V, Yalamanchili V, Merrill B, et al:Fractional flow reserve versus intravascular ultrasound fordecision making in equivocal left mein stenosis. Circulation 108:IV-462, 2004.
 
14) Mintz GS, Pichard AD, Kovach JA, et al:lmpact of preintervention intravascular ultrasound imaging on transcatheter treatment strategies in coronary artery disease. Am J Cardol 73:423-430, 1994.
 
15) Kotani J, Mintz GS, Rai PB, et al:Intravascular ultrasound assessment of angiographic filling defects in native coronary arteries; do they a|ways contain thrombi? J Am Coll Cardiol 44:2087-2089, 2004.
 
16) Kotani J, Nanto S, Mintz GS, et al:Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome. Circulation 106:1672-1677, 2002.
 
17) Tanaka A, Kawarabayashi T, Nishibori Y, et al:No-reflow phenomenon and lesion morphology in patients with acute myocardial infarction. Circulation 105:2148-2152, 2002.
PubMed

[18] 狭心症に対するOptical Coherence Tomography(OCT)

P.169 掲載の参考文献
1) Ambrose JA, et al:Angiographic evolution of coronary artery morphology in unstableangina. J Am Coll Cardiol 7:472-478, 1986.
 
2) Litt|e WC, et al:Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 7811157-1166, 1988.
 
3) 丹野直弘, 市村 勉,佐伯昭雄:光波反射像測定装置. 日本特許第2010042号.
 
4) Huang D, et al:Optical coherence tomography. Science 254:1178-1181, 1991,
PubMed
5) Tearney GJ, et al:Catheter-based optical imaging of a human coronary artery. Circulation 94:3013, 1996.
PubMed
6) Jang IK, et al:Visualization of tissue prolapsed between coronary stent struts by optical coherence tomography; comparison with intravascular ultrasound. Circulation 104:2754, 2001.
PubMed
7) Kume T, et al:Assessment of coronary intima-media thickness by optical coherence tomography; comparison with intravascuiar ultrasound. Circ J 69:903-907, 2005.
 
8) Kume T, et al:Measurement of the thickness of the fibrous cap by optical coherence tomography. Am Heart J 152 (4):755, e1-e4, 2006.
 
9) Yabushita H, et al:Characterization of human atherosclerosis by optical coherence tomography. Circulation 106:1640-1645, 2002.
PubMed
10) Naghavi M, etal:From vulnerable plaque to vulnerable patient; a call for new definitions and risk assessment strategies; Part I. Circulation 108:1664-1672, 2003.
 
11) Virmani R, et al:Lessons from sudden coronary death; acomprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20:1262-1275, 2000.
 
12) Kolodgie FD, et al:Pathologic assessment of the vulnerable human coronary plaque. Heart 90:1385-1391, 2004.
PubMed
13) Jang IK, et al:In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography. Circulation 111:1551-1555, 2005.
PubMed
14) Kubo T, et al:Assessment of culprit lesion morphology inacute myocardial infarction; ability of optical coherence tomography compared with intravascular ultrasound and coronaryangioscopy. J Am Coll Cardiol 50:933-939, 2007.
 
15) Low AF, et al:Technology insight; optical tomography-current status and future development. Nat Clin Pract Cardiovasc Med 3:154-162, 2006.
PubMed
16) Hong MK, et al:Comparison of coronary plaque rupture between stable angina and acutemyocardial infarction; a3-vessel intravascuiar uitrasound study in 235 patients. Circulation 110:928-933, 2004.
 
17) Kitabata H, et al:The plaque destabilization of non-culprit lesion in acute myocardial infarction; an optical coherence tomography study. American College of Cardiology 56th Annual Scientific Session, 2007,
 
18) Tanimoto T, et al:Various types of plaque disruption ina culprit coronary artery visualized byoptical coherence tomography inapatient with unstable angina. Circ J 73 (1):187-189, 2009.
 
19) Bouma BE, et al:Evaluation of intracoronary stenting by intravascular optical coherence tomography. Heart 89:317-321, 2003.
PubMed
20) Grube E, et al:Images in cardiovascular medicine; Intracoronary imaging with optical coherence tomography; a new high resolution technology providing striking visualization in the coronary artery. Circulation 106:2409-2410, 2002.
PubMed
21) Matsumoto D, et al:Neointimal coverage of sirolimus-eluting stents at 6-month follow-up; evaluated by optical coherence tomography. Eur Heart J 28:961-967, 2007.
PubMed
22) Cannon CP, et al:Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med 350:1495-1504, 2004.
PubMed
23) Nissen SE, et al:Effect of Intensive COmpared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis. JAMA 291:1071-1080, 2004.
 
24) Takarada S, et al:Effect of Statin Therapy on Coronary Fibrous-cap Thickness in Patients with Acute Coronary Syndrome; Assessment by Optical Coherence Tomography Study. Atherosclerosis 202 (2):491-497, 2009.
 

[19] 狭心症の診断における血管内視鏡

P.175 掲載の参考文献
1) Falk E, Shah PK, Fuster V:Coronary plaque disruption. Circulation 92 (3):657-671, 1995.
PubMed
2) Ueda Y, Ohtani T, Shimizu M, et al:Assessment of plaque vulnerability by angioscopic classification of plaque color. Am Heart J 148 (2):333-335, 2004.
PubMed
3) Takano M, Mizuno K, Yokoyama S, et al:Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin; serial evaluation by coronary angioscopy. J Am Coll Cardiol 42 (4):680-686, 2003.
PubMed
4) Kawano T, Honye J, Takayama T, et al:Compositional analysis of angioscopic yellow plaques with intravascular ultrasound radiofrequency data. Int J Cardio 125 (1):74-78, 2008.
 
5) McFadden EP, Stabile E, Regar E, et al:Late thrombosis in drug-elutingcoronary stents after discontinuation of antiplatelet therapy. Lancet 364 (9444):1519-1521, 2004.
PubMed
6) Kotani J, Awata M, Nanto S, et al:Incomplete neointimal coverage of sirolimus-eluting stents; angioscopic findings. J Am Coll Cardiol 47 (10):2108-2111, 2006.
PubMed

[20] 狭心症の薬物療法

P.185 掲載の参考文献
1) Boden WE, O'Rourke RA, Teo KK, et al:Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356 (15):1503-1516, 2007.
 
2) Kasanuki H, Honda T, Haze K, et al:A large-scale prospective cohort study on the current status of therapeutic modalities for acute myocardial infarction In Japan; rationale and initial results of the HIJAMI Registry. Am Heart J 150 (3):411-418, 2005.
 
3) GISSI-3:effects of lisinopriland transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction; Gruppo ltaliano per lo Studio della Sopravvivenza nell:infarto Miocardico. Lancet 343 (8906):1115-1122, 1994.
 
4) Latini R, Staszewsky L, Maggioni AP, et al:Beneficial effects of angiotensin-converting enzyme inhibitor and nitrate association on left ventricular remodeling in patients with large acute myocardial infarction; the Delapril Remodeling after Acute Myocardial Infarction (DRAMI) trial. Am Heart J 146 (1):133, 2003.
PubMed
5) Ishikawa K, Kanamasa K, Ogawa I, et al:Long-term nitrate treatment increases cardiac events in patients with healed myocardial infarction; Secondary Prevention Group. Jpn Circ J 60 (10):779-788, 1996.
PubMed
6) Nakamura Y, Moss AJ, Brown MW, et al:Long-term nitrate use may be deleterious in ischemic heart disease; A study using the databases from two large-scale postinfarction studies. Multicenter Myocardial Ischemia Research Group. Am Heart J 138 (3 Pt 1):577-585, 1999.
 
7) Yamauchi T, Hagiwara N, Kasanuki H, et al:Long-term nitrate use in acute myocardial infarction (The Heart Institute of Japan, Department of cardiology nitrate evaluation program). Cardiovasc Drugs Ther 22:177-184, 2008.
PubMed
8) Kojima S, Matsui K, Sakamoto T, et al:Long-term nitrate therapy after acute myocardial infarction does not improve or aggravate prognosis. Circ J 71 (3):301-307, 2007.
PubMed
9) Kohro T, Hayashi D, Okada Y, et al:Effects of medication on cardiovascular events in the Japanese coronary artery disease (JCAD) study. Circ J 71 (12):1835-1840, 2007.
PubMed
10) Yui Y, Sumiyoshi T, Kodama K, et al:Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease; the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 27 (3):181-191, 2004.
PubMed
11) Nissen SE, Tuzcu EM, Libby P, et al:Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure:the CAMELOT study; a randomized controlled trial. JAMA 292 (18):2217-2225, 2004.
PubMed
12) Pepine CJ, Cohn PF, Deedwania PC, et al:Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily Iife; The Atenolol Silent ischemia Study (ASIST) , Circulation 90 (2):762-768, 1994.
 
13) Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardio 193 (8):969-973, 2004.
 
14) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction:ISIS-2:ISIS-2 (Second International Study of Infarct Survival) Collaborative Group, Lancet 2 (8607):349-360, 1988.
 
15) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (7329):71-86, 2002.
PubMed
16) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (8934):1383-1389, 1994.
PubMed
17) Schwartz GG, Olsson AG, Ezekowitz MD, et al:Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes:the MIRACLstudy; a randomized controlled trial. JAMA 285 (13):1711-1718, 2001.
PubMed
18) Sakamoto T, Kojima S, Ogawa H, et al:Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol 97 (8):1165-1171, 2006.
PubMed
19) Nagashima M, Koyanagi R, Kasanuki H, et al:Effect of early statin treatment at standard doses on long-term clinical outcomes in patients with acute myocardial infarction (the Heart Institute of Japan, Department of Cardiology Statin Evaluation Program). Am J Cardiol 99 (11):1523-1528, 2007.
PubMed
20) Okazaki S, Yokoyama T, Miyauchi K, et al:Early statin treatment in patients with acute coronary syndrome; demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after co ronary event; the ESTABUSH Study. Circulation 110 (9):1061-1068, 2004.
 
21) Yasue H, Mizuno Y, Harada E, et al:Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers. J Am Coll Cardiol 51 (18):1742-1748, 2008.
PubMed
22) Yusuf S, Sleight P, Pogue J, et al:Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients; The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (3):145-153, 2000.
 
23) Dahlof B, Devereux RB, Kjeldsen SE et al:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) ; arandomised trial against atenolol, Lancet 359 (9311):995-1003, 2002.
PubMed
24) Kasanuki H, Hagiwara N, Kawana M, et al:A randomized trial of ARB-based versus non-ARB standard therapy in patients wit4h coronary artery disease and hypertension; HIJ-CREATE study. Circulation 116 (22):2632-2632, 2007.
 
25) Ogawa H, Kawana M, Tamura K, et al:Long-term prognosis of medicaliy treated patients with acute myocardial infarction and one-vessel coronary artery disease. Am J Cardio 173 (2):158-163, 1994.
 

[21] 冠動脈インターベンション(PCl)の適応

P.199 掲載の参考文献
1) Stettler C, Wandel S, Allemann S, et al:Outcomes associated with drug-eluting and baremetal stents; a collaborative network meta-analysis. Lancet 370:937-948, 2007.
PubMed
2) Mauri L. Silbaugh TS, Wolf RE, et al:Long-Term Clinical Outcomes After Drug-Eluting and Bare-Metal Stenting in Massachusetts. Circulation 118:1817-1827, 2008.
PubMed
3) Stone GW, Ellis SG, Colombo A, et al:0ff setting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation 115:2842-2847, 2007.
 
4) Grines CL Bonow RO, Casey DE Jr., et al:Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents:ascience advisory from the American Heart Association, American Coilege of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 49:734-739, 2007.
 
5) Fuster V, Badimon L, Badimon JJ, et al:The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 326:310-318, 1992,
PubMed
6) Smith SC Jr., Feldman TE, Hirshfeld JW Jr., et al:ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention; areport of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 47:e1-e121, 2006.
 
7) Thygesen K, Alpert JS, White HD, et al:Universal definition of myocardial infarction. Circulation 116:2634-2653, 2007.
PubMed
8) Ellis SG, Ajluni S, Arnold AZ, et al:Increased coronary perforation in the new device era; Incidence, classification, management, and outcome. Circulation 90:2725-2730, 1994.
PubMed
9) Ryan TJ, Faxon DP, Gunnar RM, et al:Guidelines for percutaneous transluminal coronary angioplasty; A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation 78:486-502, 1988.
 
10) Boden WE, O'Rourke RA, Teo KK, et al:Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356:1503-1516, 2007.
 
11) Weintraub WS, Spertus JA, Kolm P, et al:Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med 359:677-687, 2008.
PubMed
12) Shaw LJ, Berman DS, Maron DJ, et al:Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden; results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 117:1283-1291, 2008.
 
13) BARI Investigators:The final 10-year follow-up results from the BARI randomized trial. JAm Coll Cardiol 49:1600-1606, 2007.
 
14) Hannan EL, Wu C, Walford G, et al:Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med 358:331-341, 2008.
PubMed
15) Braunwald E, Antman EM, Beasley JW, et al:ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article; a report of the American College of Cardioiogy/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). JAm Coll Cardiol 40:1366-1374, 2002.
 
16) de Winter RJ, Wndhausen F, Cornel JH, et al:Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 353:1095-1104, 2005.
 
17) Patti G, Pasceri V, Colonna G, et al:Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention; results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 49:1272-1278, 2007.
 
18) Ong AT, Serruys PW:Complete revascularization; coronary artery bypass graft surgery versus percutaneous coronary intervention. Circulation 114:249-255, 2006.
PubMed
19) van den Brand MJ, Rensing BJ, Morel MA, et al:The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. J Am Coll Cardiol 39:559-564, 2002.
 
20) Reynolds HR, Hochman JS:Cardiogenic shock; current concepts and improving outcomes. Circulation 117:686-697, 2008
PubMed
21) Hochman JS, Lamas GA, Buller CE et al:Coronary intervention for persistent ocdusion after myocardial infarction. N Engl J Med 355:2395-2407, 2006.
PubMed
22) Allman KC, Shaw LJ, Hachamovitch R, et al:Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction; ameta-analysis. J Am Coll Cardiol 39:1151-1158, 2002.
 
23) Zimarino M, Ausiello A, Contegiacomo G, et al:Rapid decline of collateral circulation increases susceptibility to myocardial ischemia; the trade-off of successful percutaneous recanalization of chronic total occlusions. J Am Coll Cardiol 48:59-65, 2006.
PubMed
24) Seung KB, Park DW, Kim YH, et al:Stents versus coronary-artery bypass grafting for left main coronary artery disease. N Engl J Med 358:1781-1792, 2008.
PubMed
25) Al Suwaidi J, Yeh W, Cohen HA, et al:Immediate and one-year outcome in patients with coronary bifurcation lesions in the modern era (NHLBI dynamic registry). Am J Cardiol 87:1139-1144, 2001.
PubMed
26) Coolong A, Baim DS, Kuntz RE, et al:Saphenous vein graft stenting and major adverse cardiac events; a predictive model derived from a pooled analysis of 3958 patients. Circulation 117:790-797, 2008.
PubMed

[22] Drug-eluting stentについて

P.210 掲載の参考文献
1) Gregory CR, Huie P, Billingham ME, et al:Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury; lts effect on celiuiar, growth factor, and cytokine response in injured vessels, Transplantation 55 (6):1409-1418, 1993.
 
2) Yamasaki K, Asai T, Shimizu M, et al Inhibition of NFkappaB activation using cis-element 'decoy' of NF kappaB binding site reduces neointimal formation in porcine balloon-injured coronary artery model. Gene Ther 10:356-364, 2003.
PubMed
3) Giannakakou P, Robey R, Fojo T, et al:Low concentration of paclitaxel induce cell type dependent p53, p21 and G1/G2 arrest instead of mitotic arrest; molecular determinants of paciitaxel-induced cytotoxicity. Oncogene 20:3806-3813, 2001.
PubMed
4) Axel Dl, Kunert W, Goggelmann C, et al:Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96:636-645, 1997.
 
5) Karyekar CS, Pradhan RS, Freeney T, et al:A phase l multipie-dose escalation study characterizing pharmacokinetics and safety of ABT-578 in healthy subjects. J Clin Pharmacol 45:910-918, 2005.
 
6) Zheng H, Barragan P, Corcos T, et al:Clinical experience with a new biocompatible phosphorylcholine-coated coronary stent. J Invasive Cardiol 11 (10):608-614, 1999.
 
7) Morice MC, Serruys PW, Sousa JE, et al:A randomized comparison of a Sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773-1780, 2002.
PubMed
8) Morice M-C, Serruys PW, Barragan P, et al:Long-term clinical outcomes with sirolimuseluting coronary stents. J Am Coll Cardiol 50:1299-1304, 2007.
PubMed
9) Moses JW, Leon MB, Popma JJ, et al:Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315-1323, 2003.
 
10) Morice MC, Colombo A, Meier B, et al:Sirolimus-eluting vs paclitaxel-eluting stents in de novo coronary artery lesions; the REALITY trial; arandomized controlled trial. JAMA 295 (8):895-904, 2006.
 
11) Smith SC, Feldman TE, Hirshfeld JW, et al:ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. pp80-90, The American College of Cardiology Foundation and American Heart Association, Washington DC, and Dallas, 2005.
 
12) Spencer BK, Sidney CS, John WH, et al:2007 Focused update of ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Circulation 117:261-295, 2008.
 
13) Colombo A, Moses J W, Morice MC, et al:Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 109:1244-1249, 2004.
PubMed
14) Tanabe K, Hoye A, Lemos PA, et al:Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings. Am J Cardiol 94:115-118, 2004.
 
15) Park SJ, Kim YH, Lee BK, et al:Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis. J Am Coll Cardiol 45:351-356, 2005.
PubMed
16) Valgimigli M, Malagutti P, Aoki J, et al:Sirolimus-eluting versus paclitaxei-eluting stent implantation for the percutanous treatment of left main coronary artery disease; a combined RESEARCH and T-SEACH long-term analysis. J Am Coll Cardiol 47:507-514, 2006.
 
17) Costa MA, Simon Dl:Molecular basis of restenosis and drug-eluting stents. Circulation 111:2257-2273, 2005.
 
18) Corbett SJ, Cosgrave J, Melzi G, et al:Petterns of restenosis after drug-eluting stent implantation; insight from a contemporary and comparative analysis of sirolimus-and paclitaxel-eluting stents. Eur Heart J 27:2330-2337, 2006.
 
19) McFadden EP, Stabile E, Regar E et al:Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364:1519-1521, 2004.
PubMed

[23] 安定狭心症の治療指針

P.219 掲載の参考文献
1) Gibbons RJ, Abrams J, Chatterjee K, et al:ACC/AHA 2002 guideline update for the management of patients with chronic stable angina; areport of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients with Chronic Stable Angina). 2002 (Available at www.acc.org/clinical/guideiines/stable/stable. pdf).
 
2) Fraker TD Jr, Fihn SD, writing on behalf of the 2002 Chronic Stable Angina Writing Committee:2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina; areport of the American Coilege of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to Deveiop the Focused Update of the 2002 guidelines for the management of patients with chronic stable angina. Circulation 116:2762-2772, 2007.
 
3) Fox K, Gracia MAA, Ardissino D, et al:The task force on the management of stable angina pectoris of the European Society of Cardiology. 2006 (Available at http://www.escardio.org/knowledge/guidelines/Management_Stable_Angina_Pectoris. htm).
 
4) Califf RM, Armstrong PW, Carver JR, et al:Task Force 5. Stratification of patients into high-, medium-and low-risk subgroups for purposes of risk factor management. J Am Coll Cardiol 27:1007-1019, 1996.
PubMed
5) Morrow DA, Gersh BJ:Chronic coronary artery disease. Braunwald:s heart disease; a textbook of cardiovascular medicine, 8th ed, Libby P, Bonow RO, Mann DL, et al (eds), pp1353-1417, Saunders, Philadelphia, 2008.
 
6) 藤原久義, 阿彦忠之, 飯田真美, ほか:循環器病の診断と治療に関するガイドライン; 禁煙ガイドライン. Circ J 69 (Suppl IV):1005-1103, 2005.
 
7) 石川欽司, 上島浩嗣, 小川久雄, ほか:循環器病の診断と治療に関するガイドライン; 心筋梗塞二次予防に関するガイドライン (2006年改訂版) (Available at http://www.j-circ.or.jp/guideline/pdf/JCS2006_shikawa_h.pdf).
 
8) Boden WE, O'Rourke RA, Teo KK, et al:Optimal Medical Therapy with or without PCI for Stable Coronary Disease. N Engl J Med 356:1503-1516, 2007.
 
9) King SB III:The COURAGE trial; is there stillarolefor PCI in stable coronary artery disease? Nature Clin Pract Cardiovasc Med 4:410-411, 2007.
 
10) Fujiwara H, Nishigaki K, J-SAP study group:Japanese stable angina pectoris (JSAP) study:A randomized comparative multi-center study between PCI-medical and medical-preceding therapies. Int J Cardiol 122 (Suppl):7, 2007.
 

[24] 不安定狭心症の治療指針

P.227 掲載の参考文献
1) The joint ESC/ACC committee:Myocardial infarction redefined-a consensus document of the joint European Society of Cardiology/American College of Cardioiogy committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36:659-969, 2000.
 
2) Antman EM, et al:2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-Elevation Myocardial nfarction; areport of the American College of Cardiology/American Heart Association task force on practice guidelines (writing group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-Elevation Myocardial Infarction). J Am Coll Cardiol 51:210-247, 2008.
 
3) Report of the Ad Hoc COmmittee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association:Areporting system on patients evaluated for coronary artery disease. Circulation 51:5-40, 1975.
 
4) Braunwald E:Unstable angina; A classification. Circulation 80:410-414, 1989.
PubMed
5) Anderson JL, et al:ACC/AHA 2007 guidelines forthe management of patients with unstabieangina/non-ST-elevation myocardial infarction:executive summary; a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction). Circulation 116:803-877, 2007.
 
6) 急性冠症候群の診療に関するガイドライン (2007年改訂版) (available at http://www.j-circ.or.jp/guideline/pdf/JCS2007_yamaguchLh.pdf).
 
7) The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators:Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation. N Engl J Med 345:494-502, 2001.
PubMed
8) Bavry AA, et al:Benefit of early invasive therapy in acute coronary syndromes; Ameta analysis of contemporary randomized clinical trials. J Am Coll Cardiol 48:1319-1325, 2006.
 

[25] 冠攣縮性狭心症の治療指針

P.235 掲載の参考文献
1) 循環器病の診断と治療に関するガイドライン (2006-2007年度合同研究班報告) ; 冠攣縮性狭心症の診断と治療に関するガイドライン. 2008 (http://www.j-circ.or.jp/guideline/pdf/JCS2008_ogawah_h.pdf).
 
2) 末田章三:カルシウム拮抗薬と冠攣縮性狭心症; 歴史と治療変遷. 呼と循53:953-961, 2005
 
3) Miwa K, Miyagi Y, Igawa A, et al:Vitamin E deficiency in variant angina. Circulation 94:14-18, 1996.
PubMed
4) Kugiyama K, Motoyama T, Hirashima O, et al:Vitamin C attenuates abnormal vasomotor reactivity in spasm coronary arteries in patients with coronary spastic angina. J Am Coll Cardiol 32:103-109, 1998.
 
5) Kawano H, Motoyama T, Hirai N, et al:Estradiol supplementation suppresses hyperventilation-induced attacks in postmenopausai women with variant angina. J Am Coll Cardiol 37:735-740, 2001.
PubMed
6) Masumoto A, Mohri M, Shimokawa H, et al:Suppression of coronary artery spasm by the Rhokinase inhibitor fasudil in patients with vasospastic angina. Circulation 105:1545-1547, 2002.
PubMed
7) Yasue H, Omote S, Takizawa A, et al:Circadian variation of exercise capacity in patients with Prinzmetal's variant angina; role of exercise-induced coronary arterial spasm. Circulation 59:938-948, 1979.
PubMed
8) Sueda S, Ochi N, Kawada H, et al:Frequency of provoked coronary vasospasm in patients undergoing coronary arteriography with spasm provocation test of acetylcholine. Am J Cardiol 83:1186-1190, 1999.
PubMed
9) Sueda S, Kohno H, Fukuda H, et al:Frequency of provoked coronary spasms in patients undergoing coronary arteriography using a spasm provocation test via intracoronary administration of ergonovine. Angiology 55:403-411, 2004.
PubMed
10) Ito A, Fukumoto Y, Shimokawa H:Changing characteristics of patients with vasospastic angina in the era of new calcium channel blockers. J Cardiovasc Pharmacol 44:480-485, 2004.
PubMed
11) Yasue H, Takizawa A, Nagao M, et al:Long-term prognosis for patients with variant angina and influential factors, Circulation 78:1-9, 1988.
PubMed
12) 末田章三, ほか:ガイドライン作成前の我が国の冠攣縮の現況; 全国冠攣縮アンケート調査結果から. Jcardiolo 48:333-343, 2006.
 
13) Waters DD, Bouvhard A, Theroux P:Spontaneous remission is a frequent outcome of variant angina J Am Coll cardiol 2:195-199, 1983.
PubMed
14) Sueda S, Kohno H, Fukuda H, et al:Limitations of medical therapy in patients with pure coronary spastic angina. Chest 123:380-386, 2003.
PubMed
15) Sueda S, Suzuki J, Watanabe K, et al:New non-invasive protocol for detection of coronary spastic angina with significant organic stenosis. Coron Artery Dis 12:295-303, 2001.
PubMed
16) Sueda S, Fukuda H, Watanabe K, et al:Usefulness of accelerated exercise following mild hyperventilation for the induction of coronary artery spasm; comparison with an acetylcholine test. Chest 119:155-162, 2001.
PubMed
17) 末田章三, ほか:冠攣縮の認識不足がもたらす将来へのリスク; 全国冠攣縮アンケート調査結果から. J Cardiol 49:83-90, 2006.
 
18) Yasue H, Nakagawa H, ltoh T, et al:Coronary artery spasm; Clinical features, diagnosis, pathogenesis, and treatment. J Cardiol 51:2-17, 2008.
 

[26] 糖尿病を合併する狭心症患者の治療

P.240 掲載の参考文献
1) Castelli WP:Cardiovascular disease and multifactorial risk; challenge of the 1980s. Am Heart J 106:1191-1200, 1983.
PubMed
2) Anonymous:Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) ; UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-853, 1998.
PubMed
3) Anonymous:Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. N Engl J Med 311:1333-1339, 1984.
 
4) Califf RM, Harrell FE Jr., Lee KL, et al:The evolution of medical and surgical therapy for coronary artery disease; a 15-year perspective. JAMA 261:2077-2086, 1989.
PubMed
5) Anonymous:Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease:The Bypass Angioplasty Revascularization Investigation (BARD Investigators. N Engl J Med 335:217-225, 1996.
 
6) Anonymous:Coronary angioplasty versus coronary artery bypass surgery; the Randomized Intervention Treatment Of Angina (RITA) trial. Lancet 341:573-580, 1993.
 
7) King SB III, Lembo NJ, Weintraub WS, et al:A randomized trial comparing coronary angioplasty with coronary bypass surgery; Emory Angioplasty versus Surgery Trial (EAST). N Engl J Med 331:1044-1050, 1994.
 
8) Anonymous:First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation) ; CABRI Triai Participants. Lancet 346:1179-1184, 1995.
 
9) Anonymous:Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease; the Bypass Angioplasty Revascularization Investigation (BARD. Circulation 96:1761-1769, 1997.
 
10) Anonymous:Coronary artery surgery study (CASS) ; a randomized trial of coronary artery bypass surgery; Survival data. Circulation 68:939-950, 1983.
 
11) Hueb WA, Bellotti G, De Oliveira SA, et al:The Medicine, Angioplasty or Surgery Study (MASS) ; a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. J Am Coll Cardiol 26:1600-1605, 1995.
PubMed
12) Gibbons RJ, Chatterjee K, Daley J, et al:ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina; areport of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 33:2092-2197, 1999.
 
13) Otsuka Y, Miyazaki S, Okumura H, et al:Abnormal glucose tolerance, not small vessel diameter, is a determinant of long-term prognosis in patients treated with balbon coronary angioplasty. Eur Heart J 21:1790-1796, 2000.
PubMed
14) Kataoka Y, Yasuda S, Morii l, et al:Quantitative coronary angiographic studies of patientswith angina pectoris and impaired glucose tolerance. Diabetes Care 28:2217-2222, 2005.
 
15)Morice MC, Serruys PW, Sousa JE, et al:A randomized comparison of a sirolimus-elutingstentwith a standard stent for coronary revascularization, N Engl J Med 346:1773-1780, 2002.
PubMed
16)McFadden EP, Stabile E, Regar E, et al:Late thrombosis indrug-eluting coronary stents afterdiscontinuation of antiplatelet therapy. Lancet 364:1519-1521, 2004.
 
17)Serruys PW, Unger F, Sousa JE, et al:Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 344:1117-1124, 2001.
PubMed
18)Serruys PW, Lemos PA, Van Hout BA:Sirolimus eluting stent implantation for patients with multivessel disease; rationale for the Arterial Revascularisation Therapies Study part II (ARTS II). Heart 90:995-998, 2004.
PubMed
19)Chiasson JL, Josse RG, Gomis R, et al:A carbose treatment and the risk of cardiovasculardisease and hypertension in patients with impaired glucose tolerance; the STOP-NIDDM trial. JAMA 290:486-494, 2003.
 
20)Dormandy JA, Charbonnel B, Eckland DJ, et al:Secondary prevention of macrovascularevents in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial Inmacrovascular Events) ; a randomised controlled trial. Lancet 366:1279-1289, 2005
PubMed

[27] 腎疾患を合併する狭心症患者の治療

P.248 掲載の参考文献
1) Go AS, et al:Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296-1305, 2004.
PubMed
2) Kurella M, et al:Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 16:2134-2140, 2005.
PubMed
3) Ninomiya T, et al:Metabolic syndrome and CKD in a general Japanese population; the Hisayama Study. Am J Kidney Dis 48:383-391, 2006.
 
4) Kohro T, et al:Effects of medication on cardiovascular events in the Japanese coronary artery disease (JCAD) study Circulation J 71:1835-1840, 2007.
 
5) Kitakaze M, et al:Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardiai infarction (J-WIND) ; two randomised trials. Lancet 370:1483-1493, 2007.
 
6) Ishii H, et al:Efficacy of oral nicorandil in patients with end-stage renal disease; a retrospective chart review after coronary angioplasty in Japanese patients receiving hemodialysis. Clin Ther 29:110-122, 2007.
PubMed
7) Fujita T, et al:Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kid International 72:1543-1549, 2007.
 
8) Ishii H, et al:Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease. Clin J Am Soc Nephrol 3:1034-1040, 2008.
PubMed
9) Hemmelgarn BR, et al:Survival after coronary revascularization among patients with kidney disease. Circulation 110:1890-1895, 2004.
PubMed
10) Aoyama T, et al:Sirolimus-eluting stents vs bare metal stents for coronary intervention in Japanese patients with renal failure on hemodialysis. Circ J 72:56-60, 2008.
PubMed
11) Nakazawa G, et al:lmpact of renai insufficiency on clinical and angiographic outcomes foilowing percutaneous coronary intervention with sirolimus-eluting stents. Catheter Cardiovasc Interv 69:808-814, 2007.
 
12) Herzog CA, et al:Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes, Circulation 106:2207-2211, 2002.
PubMed

[28] 脂質異常症を合併する狭心症患者の治療

P.259 掲載の参考文献
1) 日本動脈硬化学会:動脈硬化性疾患予防ガイドライン2007年版. 協和企画, 東京, 2007.
 
2) Nakamura Y, et al:NIPPON DATA 80. Ciruculation J 70:980-984, 2006.
 
3) Matsuzaki M, Kita T, Mabuchi H, et al; the J-LIT Study Group:Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low dose simvastatin therapy in Japanese patients with hypercholesterolemia Circulation J 66:1087-1095, 2002.
 
4) Nakamura H, Arakawa K, ltakura H, et al; MEGA Study Group:Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study) ; aprospective randomized controlled trial Lancet 368:1155-1163, 2006.
 
5) Nissen SE, Tuzcu EM, Schoenhagen P, et al; Reversal of Atherosclerosis with Aggressive Lipid Lowering Investigation:Stain therapy, LDL cholesterol, C reactive protein, and coronary artery disease. N Engl J Med 352:29-38, 2005.
 
6) Strandberg TE, Tilvis RS, Pitkala KH, et al:Cholesterol and glucose metabolism and recurrent cardiovascularevents among the elderly; a prospective study. J Am Coll Cardio 148 (4):708-714, 2006.
 
7) Ballantyne CM, Houri J, Notarbartolo A, et al:Effect of ezemitibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia; aprospective randomized, double-blind trial. Circulation 107:2409-2415, 2003.
 
8) Keech A, Simes RJ, Barter P, et al:Effects of long-term fenofibrate therapy on cardiovascular Events in 9795 people with type 2 diabetes mellitus (the FIELD study) ; randomized controlled trial. Lancet 366:1849-1861, 2005.
PubMed
9) Yokoyama M, Origasa H, Matuzaki M, et al; Japan intervention study Investigators:Effects of eicosapentaenoic acid on majorcoronary events in hypercholesterolaemic patients (JELIS) ; a randomized Openlabel, blineded endpoint analysis. Lancet 369:1090-1098, 2007.
 

[29] 冠動脈バイパス術(CABG)

P.264 掲載の参考文献
1) Mueller RL, Rosengart TK, lsom OW:The history of surgery for ischemic heart disease. Ann Thorac Surg 63:869-878, 1997.
 
2) Eagle KA, Guyton RA, Davidoff R, et al:ACC/AHA 2004 guideline update for coronary artery bypass graft surgery; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guldelines for Coronary Artery Bypass Graft Surgery). Clrculatlon 110:e340-e437, 2004.
 
3) 日本循環器学会, ほか:循環器病の診断と治療に関するガイドライン (2004-2005年度合同研究班報告) ; 虚血性心疾患に対するバイパスグラフトと手術術式の選択ガイドライン. Circ J 70 (Suppl IV):1477-1553, 2006.
 
4) Hannan EL, Wu C, Walford G, et al:Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med 358:331-341, 2008.
PubMed
5) Puskas J, Cheng D, Knight J, et al:Off-pump versus conventional coronary artery bypass grafting; ameta-analysis and consensus statement from The 2004 ISMICS Consensus Conference. Innovations 1:3-27, 2005.
 
6) Ueda Y, Osada H, Osugi H; Japanese Association for Thoracic Surgery Committee for Scientific Affairs:Thoracic and cardiovascular surgery in Japan during 2005; Annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 55:377-399, 2007.
PubMed
7) Fukui T, Takanashi S, Hosoda Y, et al:Earlyand midterm results of off-pump coronary artery bypass grafting. Ann Thorac Surg 83:115-119, 2007.
 
8) Nashef SA, Roques F, Michel P, et al:European system for cardiac Operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 16:9-13, 1999.
 
9) Sergeant P, Blackstone E, Meyns B:Validation and interdependence with patient-variables of the influence of procedural variables on early and late survival after CABG; K. U. Leuven Coronary Surgery Program. Eur J Cardiothorac Surg 12:1-19, 1997.
 
10) BARI Investigators:The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol 49:1600-1606, 2007.
 
11) Shah PJ, Hare DL, Raman JS, et al:Survival after myocardial revascularization for ischemic cardiomyopathy; a prospective ten-year follow-up study. J Thorac Cardiovasc Surg 126:1320-1327, 2003.
PubMed
12) Loop FD, Lytle BW, Cosgrove DM, et al:Influence of the internai-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med 314:1-6, 1986.
 
13) Lytle BW, Blackstone EH, Loop FD, et al:Two internal thoracic artery grafts are better than One. J Thorac Cardiovasc Surg 117:855-872, 1999.
 
14) The Post Coronary Artery Bypass Graft Trial Investigators:The effect of aggressive lowering of low-density lipoprotein choiesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 336:153-162, 1997.
PubMed

[30] 重症冠動脈病変に対する冠動脈インターベンション

P.272 掲載の参考文献
1) Bentivoglio LG, VanRaden MJ, Kelsey SF, et al:Percutaneous transluminal coronary angioplasty (PTCA) mpatients with relative contraindications; results of the National Heart, Lung, and Blood Institute PTCA registry. Am J Cardiol 53:82C-88C, 1984.
 
2) O'Keefe JH, Hartzler GO, Rutherford BD, et al:Left main coronary angioplasty; early and late results of 127 acute and elective procedures. Am J Cardiol 64:114-147, 1989.
 
3) Eldar M, Schulhoff RN, Hertz I, et al:Results of percutaneous transluminal coronary angioplasty of the left main coronary artery. Am J Cardiol 68:255-256, 1991.
 
4) Macaya C, Alfonso F, Iniguez A, et al:Stenting of elastic recoil during coronary angioplasty of the left main coronary artery. Am J Cardiol 70:105-107, 1992.
PubMed
5) Laham RJ, Carrozza JP, Baim DS:Treatment of unprotected left main stenoses with Palmaz-Schatz stenting. Cathet Cardiovasc Diagn 37:77-80, 1996.
PubMed
6) Nakamura S, Udayachalerm W, Tresukosol D, et al:Durable Clinical Benefit Following Sirolimus-Eluting Stent Deployment on the Outcome of Patients with Unprotected Left Main Coronary Arteries; Multicenter Registry in Asia. J Am Coll Cardiol 45 (Suppl A):4A, 1094, 2005.
 
7) Nakamura S, Udayachalerm W, Tresukosol D, et al:Comparison of Efficacy and Safety Between Sirolimus-Eluting Stent (Cypher(R)) and Paclitaxel-Eluting Stent (TAXUS(R)) in Unprotected Left Main Coronary Arteries; Multicenter Registry in Asia. J Am Coll Cardiol 85 A (Suppl A):866-868, 2005.
 
8) Nakamura S, Udayachalerm W, Tresukosol D, et al:Drug-Eluting Stents for the Treatment of Left Main Coronary Arteries; A Comparison of Serial Angiographic Follow-Up with Sirolimus, Paclitaxel, Zotarolimus and Tacrolimus-Eluting Stent; Multicenter Registry in Asia. Circulation 114 (Suppl II:687):3243, 2006.
 
9) Nakamura S, Bae JH, Cahyadi YH, et al:Comparison of Efficacy and Durability between Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent in Unprotected Left Main Coronary Arteries; Multicenter Registry in Asia. Circulation 116 (Suppl:II665):2976, 2007.
 
10) Nakamura S, Bae JH, Cahyadi YH, et al:Comparison of efficacy and durability of Sirolimuseluting stent and Paclitaxel-eluting stent in patients with chronic total occlusions; Multicenter Registry in Asia. Eur Heart J 29 (Suppl:681):2008.
 
11) Nakamura S, Bae JH, Cahyadi YH, et al:lmpact of sirolimus-eluting stents on the outcome of patients with chronic total occlusions; multicenter registry in Asia. J Am Coll Cardiol 43 (Suppl A:35 A):1024-1049, 2004.
 
12) Morice MC:A cardiovascular surgeons perspective on treatment of multi-vessel disease and left main-The SYNTAX trial. European Society of Cardiology, ESC Congress, 2008.
 

[31] 薬物療法、PCI、CABGの対比

P.280 掲載の参考文献
1) Boden WB, O'Rourke RA, Teo KK, et al:Optimal medical therapy with or without PCI for stable coronary artery disease. N Engl J Med 356:1503-1516, 2007.
PubMed
2) Tanihata S, Nishigaki K, Kawasaki M, et al:Outcome of patients with stable low-risk coronary artery disease receiving medical-and PCI-preceding therapies in Japan; J-SAP study 1-1. Circ J 70:365-369, 2006.
PubMed
3) Parisi F, Folland ED, Hartigan P, et al:A comparison of angioplasty and medical therapy in the treatment of single-vessel coronary artery disease; Veterans Affairs ACME Investigators. N Engl J Med 326:10-16, 1992.
 
4) Henderson RA, Pocock SJ, Clayton TC, et al:Seven-year outcome in the RITA-2 trial; coronary angioplasty versus medical therapy. J Am Coll Cardiol 42:1161-1170, 2003.
PubMed
5) Kastrati A, Mehilli J, Pache J, et al:Analysis of 14trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356:1030-1039, 2007.
PubMed
6) 日本循環器学会, ほか:冠動脈疾患におけるインターベンション治療の適応ガイドライン (冠動脈バイパス術の適応も含む) ; 待機的インターベンション. Jpn Circ J 64 (Suppl IV):1009-1022, 2000.
 
7) ACC/AHA/SCAI 2005 Guideline update for percutaneous coronary inter>ention. J Am Coll Cardiol 47:e1-e121, 2006.
 
8) Serruys PW, Ong AT, van Herwerden LA, et al:Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease; the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 46 (4):575-581, 2005.
 
9) SoS Investigators:Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation patients with multivessel coronary artery disease (the Stent or Surgery trial; arandomised controlled trial. Lancet 28 (360):965-970, 2002.
PubMed
10) Morrison DA, Sethi G, Sacks J, et al:Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass; amulticenter, randomized trial; Investigators of the Department of Veterans Affairs Cooperative Study#385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). J Am Coll Cardiol 38 (1):143-149, 2000.
 
11) Rodriguez A, Bernardi V, Navia J, et al:Argentine Randomized Study; Coronary Angioplasty with Stenting versus Coronary Bypass Surgery inpatients with Multiple-Vessel Disease (ERACI II) ; 30-day and one-year follow-up results. ERACI Investigators. J Am Coll Cardiol 37:51-58, 2001.
 
12) Hannan EL, Wu C, Walford G, et al:Drug-eluting stents vs, coronary-aretry bypass grafting in multivessel coronary artery disease. N Engl J Med 358:331-341, 2008.
 

[32] 血管新生療法

P.289 掲載の参考文献
1) Mannheimer C, Camic P, Chester MR, et al:The problem of chronic refractory angina; report from the European Soclety of Cardiology join study group on the treatment of refractory angina. Eur Hear J 23:355-370, 2002.
 
2) Asahara T, Murohara T, Sulllvan A, et al:lsolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967, 1997.
 
3) Isner J, Pieczek A, Schainfeld R, et al:Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patlent with ischemic llmb. Lancet 348:370-374, 1996.
 
4) Losordo DW, Vale PR, Symes JF, et al:Gene therapy for myocardlal angiogenesis; initial clinical results with direct myocardial Injection of phVEGF165 as sole therapy for myocardial lschemia. Circulation 98:2800-2804, 1998.
 
5) Kuethe F, Figulla HR, Herzau M, et al:Treatment with granulocyte colony-stimulating factor for mobilization of bone marrow cells in patients wlth acute myocardial infarction. Am Heart J 150:115, 2005.
 
6) Ince H, Petzsch M, Kleine HD, et al:Preservation from left ventricular remodeling by front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by use of granulocyte-colony-stimulating factor (FIRSTUNE-AMI). Circulation 112:3097-3106, 2005.
PubMed
7) Valgimigli M, Rigolin GM, Cittanti C, et al:Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans; clinical and angiographic safety profile. Eur Heart J 26:1838-1845, 2005.
PubMed
8) Zohlnhofer D, Ott I, Mehilli J, et al:Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction; arandomized controlled trial. JAMA 295:1003-1010, 2006.
 
9) Ripa RS, Jorgensen E, Wang Y, et al:Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction; result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. Circulation 113:1983-1992, 2006.
PubMed
10) Takano T, Hasegawa H, Kuwabara Y, et al:Feasibility of granulocyte colony-stimulationg factor treatment in patients with acute myocardial infarction. Int J Cardiol 122141-47, 2007.
 
11) Kang HJ, Kim HS, Zhang SY, et al:Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulatingfactor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction; the MAGIC cell randomized clinical trial. Lancet 363:751-756, 2004,
 
12) Iwama H, Uemura S, Naya N, et al:Cardiac expression of placental growth factor predicts the improvement of chronic phase left ventricular function in patients with acute myocardial infarction. J Am Coll Cardiol 47:1559-1567, 2006.
PubMed
13) Orlic D, Kajstura J, Chimenti S, et al:Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 98:10344-10349, 2001.
PubMed
14) Nygren JM, Jovinge S, Breitbach M, et al:Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med 10:494-501, 2004.
 
15) Tatsumi T, Ashihara E, Yasui T:Intracoronary transplantation of non-expanded peripheral blood-derived mononuclear cells promotes improvement of cardiac runction in patients with acute myocardial infarction. Circ J 71:1199-1207, 2007.
PubMed
16) Strauer BE, Brehm M, Zeus T, et al:Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 106:1913-1918, 2002.
PubMed
17) Assmus B, Schachinger V, Teupe C, et al:Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 106:3009-3017, 2002.
PubMed
18) Schachinger V, Assmus B, Britten MB, et al:Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction; final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 44:1690-1699, 2004.
 
19) Wollert KC, Meyer GP, Lotz J, et al:Intracoronary autologous bone-marrow celltransferafter myocardial infarction; the BOOST randomised controlled clinical trial. Lancet 364:141-148, 2004.
PubMed
20) Bartunek J, Vanderheyden M, Vandekerckhove B, et al:Intracoronary injection of CDI 33-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction; feasibility and safety. Circulation 112:1178-1183, 2005.
 
21) Lunde K, Solheim S, Aakhus S, et al:Intracoronary injection of mononuclear bone marrow celis in acute myocardial infarction. N Engl J Med 355:1199-1209, 2006.
 
22) Janssens S, Dubois C, Bogaert J, et al:Autobgous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction; double-blind, randomised controlled trial. Lancet 367:113-121, 2006.
PubMed
23)Meyer GP, Wollert KC, Lotz J, et al:Intracoronary bone marrow cell transfer after myocardialinfarction; eighteen months:follow-up data from the randomized, controiled BOOST (Bonemarrow transfer to enhance ST-elevation infarct regeneration) trial. Circulation 113:1287-1294, 2006.
 
24)Schachinger V, Erbs S, Elsasser A, et al:Intracoronary bone marrow-derived progenitor cellsin acute myocardial infarction. N Engl J Med 355:1210-1221, 2006.
 
25)Perin EC, Dohmann HF, Borojevic R, et al:Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 107:2294-2302, 2003.
PubMed
26)Perin EC, Dohmann HF, Borojevic R, et al:lmproved exercise capacity and ischemia 6 and 12months after transendocardial injection of autologous bone marrow mononuclear cells forischemic cardiomyopathy. Circulation 110 (Suppl 1):11213-11218, 2004.
 
27)Losordo DW, Schatz RA, White CJ, et al:Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina; a phase I/II adouble-blind, randomized controlled trial Circulation 115:3165-3172, 2007.
 
28)Strauer BE, Brehm M, Zeus T, et al:Regeneration of human infarcted heart muscle byintracoronary autologous bone marrow cell transplantation in chronic coronary arterydisease; the IACT Study. J Am Coll Cardiol 46:1651-1658, 2005.
 

書評

最近チェックした商品履歴

Loading...